NASDAQ:LOXO - Loxo Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$159.08 -2.39 (-1.48 %)
(As of 11/13/2018 04:00 PM ET)
Previous Close$161.47
Today's Range$158.14 - $165.04
52-Week Range$71.45 - $208.95
Volume315,200 shs
Average Volume406,300 shs
Market Capitalization$5.11 billion
P/E Ratio-29.96
Dividend YieldN/A
Beta2.26
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOXO
Previous Symbol
CUSIPN/A
Phone203-653-3880

Debt

Debt-to-Equity RatioN/A
Current Ratio3.62
Quick Ratio3.62

Price-To-Earnings

Trailing P/E Ratio-29.96
Forward P/E Ratio-63.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.30 million
Price / Sales228.61
Cash FlowN/A
Price / CashN/A
Book Value$12.63 per share
Price / Book12.60

Profitability

EPS (Most Recent Fiscal Year)($5.31)
Net Income$-148,870,000.00
Net Margins-43.49%
Return on Equity-16.42%
Return on Assets-8.66%

Miscellaneous

Employees59
Outstanding Shares30,610,000
Market Cap$5.11 billion
OptionableOptionable

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology Inc (NASDAQ:LOXO) released its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.24. The biopharmaceutical company earned $42.47 million during the quarter, compared to analyst estimates of $38.55 million. Loxo Oncology had a negative return on equity of 16.42% and a negative net margin of 43.49%. During the same period in the previous year, the company earned ($2.45) EPS. View Loxo Oncology's Earnings History.

When is Loxo Oncology's next earnings date?

Loxo Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Loxo Oncology.

What price target have analysts set for LOXO?

15 analysts have issued twelve-month price targets for Loxo Oncology's shares. Their forecasts range from $132.00 to $233.00. On average, they anticipate Loxo Oncology's share price to reach $188.1818 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Loxo Oncology.

What is the consensus analysts' recommendation for Loxo Oncology?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Loxo Oncology in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:
  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (11/10/2018)
  • 2. Citigroup Inc analysts commented, "Enbrel treats rheumatoid arthritis and related diseases and is a major contributor to Amgen’s sales and growth. We currently estimate that Enbrel sales in the psoriatic arthritis (PsA) setting account for 13% of total Enbrel sales in 2018. Enbrel’s overall market penetration likely will moderate due to completion from biosimilars outside the US and potentially in the US. We anticipate Enbrel sales to decline by approximately 6% per year from 2017-2022, but will still account for 12% of sales by 2022. However, these data presented today at ACR in PA could lead to increased adoption in the setting and provide upside to our outlook." (10/24/2018)
  • 3. Cann analysts commented, "The incidence of TRK fusion cancers has been debated in the literature, and the resulting prevalence ranges from 1,500 to 100,000 patients in the US. We continue to believe the disparities have resulted from a lack of widely used, reliable testing for TRK fusions. Data presented at the Saturday help better define the lower end of the range at 2,500-3,000 patients in the US. We believe it will be a few years into the launch of larotrectinib, when testing has improved, before we really have conviction about the actual size of the TRK fusion patient population. We currently estimate there are approximately 7,000 patients in the US, and are not making any changes to our outlook at this time." (9/17/2018)

Has Loxo Oncology been receiving favorable news coverage?

News headlines about LOXO stock have been trending positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Loxo Oncology earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:
  • Dr. Joshua H. Bilenker, Founder, Pres, CEO & Director (Age 46)
  • Ms. Jennifer Burstein, Sr. VP of Fin. (Age 46)
  • Mr. Jacob S. Van Naarden, Chief Bus. Officer (Age 33)
  • Ms. Sara Slifka, VP of Bus. Operations & Program Management
  • Ms. Jennifer L. Kronick, VP of HR

Who are Loxo Oncology's major shareholders?

Loxo Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.45%), Aisling Capital LLC (6.69%), FMR LLC (6.27%), OppenheimerFunds Inc. (3.32%), Alliancebernstein L.P. (1.88%) and FIL Ltd (1.60%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

Which major investors are selling Loxo Oncology stock?

LOXO stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, FMR LLC, FIL Ltd, OppenheimerFunds Inc., Prudential Financial Inc., Victory Capital Management Inc., Franklin Resources Inc. and Axiom International Investors LLC DE. Company insiders that have sold Loxo Oncology company stock in the last year include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Insider Buying and Selling for Loxo Oncology.

Which major investors are buying Loxo Oncology stock?

LOXO stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Brown Advisory Inc., Alliancebernstein L.P. and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Loxo Oncology.

How do I buy shares of Loxo Oncology?

Shares of LOXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of LOXO stock can currently be purchased for approximately $159.08.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $5.11 billion and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. Loxo Oncology employs 59 workers across the globe.

What is Loxo Oncology's official website?

The official website for Loxo Oncology is http://www.loxooncology.com.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  514
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel